Vincent Planche

petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI - Alzheimer's Research & Therapy Introduction Quantification of amyloid plaques (A), neurofibrillary tangles (T2), and neurodegeneration (N) using PET and MRI is critical for Alzheimer’s disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration. Methods We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T2, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge. Results petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T2, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T2/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance. Discussion petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications.

alzres.biomedcentral.com/articles/10....

Lifespan Tree of Brain Anatomy: Diagnostic Values for Motor and Cognitive Neurodegenerative Diseases The lifespan tree of brain anatomy improves multiclass differential diagnosis of neurodegenerative diseases by modeling brain volume changes over time. It outperforms SVM, provides interpretable dise...

onlinelibrary.wiley.com/doi/10.1002/...

Using brain charts that map structural changes in the brain across the human lifespan, Planche et al. estimate the neurodegenerative trajectories of the three major genetic forms of frontotemporal lobar degeneration. tinyurl.com/2s3uhdpw

By combining brain charts for the human lifespan and 1,341 MRIs from subjects with a FTLD mutation, we described the age of onset of the first anatomical abnormalities, the duration of the presymptomatic phase, the chronological staging of atrophy progression, and the severity of regional atrophy.

Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan Using brain charts that map structural changes in the brain across the human lifespan, Planche et al. estimate the neurodegenerative trajectories of the th

I’m very happy 🥳 to share our new collaborative work, just published in Brain!🧠 academic.oup.com/brain/advanc...

Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques - npj Parkinson's Disease npj Parkinson's Disease - Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques

📰 New article published in NPJ Parkinson's Disease: "Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques" 🧠
✒️ By M. Darricau, ML Arotçarena, @benjamindehay.bsky.social, E. Bezard and @vincentplanche.bsky.social
📌 For more: www.nature.com/articles/s41...

This letter, co-written with @suzanneeschindler.bsky.social , David Knopman, Giovanni Frisons, Douglas Galasko, Joshua Grill, Lon S. Schneider, Jason Karlawish and @nvillain-alz.bsky.social , is a response to the previously published Perspective Article by Paul Aisen and colleagues.

The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence Click on the article title to read more.

am pleased to share our letter, highlighting that the science does not yet support regulatory approval of amyloid-targeting therapies for AD based solely on biomarker evidence.
alz-journals.onlinelibrary.wiley.com/doi/full/10....

Reducing Misdiagnosis with Alzheimer’s Blood Biomarkers and Cognitive Phenotyping Discover how cognitive profiles refine Alzheimer’s blood test results. Find out more.

www.emjreviews.com/neurology/ne...

Many thanks to Erwan Bezard, who co-lead this work, and to all the co-authors: Valentine Kulifaj, Marie-Laure Arotçarena, Qin Li, Taxiarchis Katsinelos, William A. McEwan, Maria Xilouri, and @benjamindehay.bsky.social DEHAY!

Taken together, our findings align with the growing body of literature indicating that co-pathologies can significantly influence the severity and progression of neurodegenerative diseases.

We found that the distant injection of LB or AD-tau induced nigral TH neuronal loss of 26.5% and 38.4%, respectively. Notably, the co-injection of these aggregates into distinct but anatomically connected regions to the mesencephalon resulted in an additive effect with 53.5% neuronal loss

we reported for the first time the cooperation between LB and tau pathologies in this experimental context. We found that the injection of AD-tau could induce distant pSyn, whereas we did not observe the reverse phenomenon; the injection of LB did not induce distant AT8-positive tau phosphorylation

We used in this study our innovative approach consisting of injecting patient-derived proteopathic aggregates into macaques’ brains, to address the issue of a putative contribution of tau versus α-synuclein pathologies to the survival of dopaminergic mesencephalic neurons.

Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques - npj Parkinson's Disease npj Parkinson's Disease - Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques

I'm delighted to share the new work by Morgane DARRICAU, just published in NPJ Parkinson's Disease!

Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaques
www.nature.com/articles/s41...

Maladie d’Alzheimer : ce neurologue bordelais veut rendre son diagnostic plus précis Vincent Planche, neurologue bordelais, également enseignant et chercheur, travaille sur la maladie d’Alzheimer depuis 2017. Il vient notamment d’être récompensé par la Fondation de France pour ses

📰 Retrouvez dans @sudouest.fr les travaux de @vincentplanche.bsky.social @imn-bordeaux.bsky.social et praticien hospitalier @chu-bordeaux.fr , sur le diagnostic de la maladie d'Alzheimer et sa précision, encore perfectible :
www.sudouest.fr/giro...

Maladie d’Alzheimer : ce neurologue bordelais veut rendre son diagnostic plus précis Vincent Planche, neurologue bordelais, également enseignant et chercheur, travaille sur la maladie d’Alzheimer depuis 2017. Il vient notamment d’être récompensé par la Fondation de France pour ses tra...

[#PRESSE]"Maladie d’Alzheimer ce neurologue bordelais veut rendre son diagnostic plus précis" avec le Dr Vincent Planche neurologue au @chu-bordeaux.fr enseignant chercheur qui travaille sur la maladie d'#Alzheimer @sudouest.fr www.sudouest.fr/gironde/bord...
@univbordeaux.bsky.social @inserm.fr

Lien vers le communiqué de presse "vers la définition d’un cadre d’utilisation des biomarqueurs sanguins
de la maladie d’Alzheimer en pratique clinique" : www.chu-bordeaux.fr/Espace-m%C3%...

Interpreting p-tau-17 results depends on characterizing the clinical phenotype.

Positive predictive value in those w/ subjective cognitive impairment was only 60%. It was 90% in those with MCI & a typical Alzheimer phenotype.

Important to consider before widespread use of blood-based biomarkers.

Just out in JAMA Neurol blood biomarkers are powerful—but without cognitive phenotyping, we risk more noise than signal.
Plasma p-tau217 needs clinical context or we’ll end up in a false-positive factory!
Clinico-biological AD is a reality!
👉🏻 jamanetwork.com/journals/jam...

bsky.app/profile/vinc...

The main message of this study is that neuropsychological examination remains fundamental for interpreting the results of AD plasma biomarkers (ptau217)

Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers This cohort study investigates if the clinical phenotype of patients without dementia is associated with blood phosphorylated tau 217 interpretation.

Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...

Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics Lecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of earl…

1/ NEW: Lecanemab in France
The French Federation of Memory Clinics just released its appropriate use recommendations for #Lecanemab in early #Alzheimers. What’s new? How does it compare to U.S. guidelines? A thread 🧵⬇️

www.sciencedirect.com/science/arti...

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

AD and PD, same battle! Biology, yes, but not in isolation from clinical practice! Happy to share David Bendetowicz paper: Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease journals.sagepub.com/doi/10.1177/...

Should amyloid-lowering therapies be approved based on biomarker evidence alone?

With @vincentplanche.bsky.social we argue for prioritizing clinical endpoints over unvalidated surrogates like amyloid load in AD trials. Read our full critique on AlzForum: www.alzforum.org/news/researc...

Cognitive screening instruments: time for retirement Cognitive screening instruments are used daily in clinics devoted to the assessment of cognitive disorders and also in general neurology clinics where patients with complaints of memory disorder may b...

There are many reasons why the suggestion to abandon examining our patients in behavioral neurology is a bad idea. One that is often overlooked regarding bedside cognitive screening, is that it allows the family to appreciate the level of mental functioning. #endalz

pn.bmj.com/content/earl...

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease - Nature Reviews Neurology Anti-amyloid treatments for early symptomatic Alzheimer disease have greatly increased the need for biomarker confirmation of amyloid pathology and blood biomarker tests offer an accessible and scalab...

The interpretation of blood tests in terms of predictive values depends on the pre-test probability of being amyloid-positive, and therefore on the clinical context. So clinic first! See @suzanneeschindler.bsky.social paper for the global CEO initiative: www.nature.com/articles/s41...

Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease - Nature Reviews Neurology Anti-amyloid treatments for early symptomatic Alzheimer disease have greatly increased the need for biomarker confirmation of amyloid pathology and blood biomarker tests offer an accessible and scalab...

The interpretation of blood tests in terms of predictive values depends on the pre-test probability of being amyloid-positive, and therefore on the clinical context. So clinic first! See @suzanneeschindler.bsky.social paper for the global CEO initiative: www.nature.com/articles/s41...

The body of the text discusses all the well-known limitations of these screening tests, which must, of course, be taken into account. However, placing biological screening at the same level or even suggesting it as a replacement for clinical screening will lead to dramatic diagnostic errors

😡 we should thank the AA. 😡